xml: <clinical_study>
    <!-- This xml conforms to an XML Schema at:
      https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
    <required_header>
      <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
      <link_text>Link to the current ClinicalTrials.gov record.</link_text>
      <url>https://clinicaltrials.gov/ct2/show/NCT05986981</url>
    </required_header>
    <id_info>
      <org_study_id>PekingUMCHVaccineMUC1</org_study_id>
      <nct_id>NCT05986981</nct_id>
    </id_info>
    <brief_title>MUC1 Therapeutic Tumor Vaccine in Advanced Solid Cancers</brief_title>
    <official_title>Single-arm, Open-label Clinical Study on the Safety, Tolerability, and Preliminary Efficacy of MUC1 Therapeutic Tumor Vaccine in Advanced Solid Cancers</official_title>
    <sponsors>
      <lead_sponsor>
        <agency>Peking Union Medical College Hospital</agency>
        <agency_class>Other</agency_class>
      </lead_sponsor>
    </sponsors>
    <source>Peking Union Medical College Hospital</source>
    <oversight_info>
      <is_fda_regulated_drug>No</is_fda_regulated_drug>
      <is_fda_regulated_device>No</is_fda_regulated_device>
    </oversight_info>
    <brief_summary>
      <textblock>
        This is an investigator-initiated, single-center, open, single-arm, exploratory study of a&#xD;
        therapeutic cancer vaccine for the treatment of advanced solid tumors. A dose-escalation&#xD;
        trial is being conducted in subjects diagnosed with advanced solid tumors to evaluate the&#xD;
        safety and tolerability of the cancer vaccine in subjects with advanced solid tumors and to&#xD;
        preliminarily evaluate the efficacy of the tumor vaccine in subjects with advanced solid&#xD;
        tumors.&#xD;
      </textblock>
    </brief_summary>
    <detailed_description>
      <textblock>
        Malignant tumours have become one of the major public health problems that seriously threaten&#xD;
        human health. According to the latest global cancer burden data for 2020 released by the&#xD;
        International Agency for Research on Cancer (IARC) of the World Health Organization (WHO),&#xD;
        there will be 19.29 million new cancer cases and 9.96 million deaths globally in 2020; in&#xD;
        2020, there will be 4.57 million new cancer cases and 3 million deaths in China, with the&#xD;
        number of new cancers in China accounting for 23.7% of the global incidence and 30% of the&#xD;
        global deaths, both of which are the highest in the world. The number of new cancer cases in&#xD;
        China accounts for 23.7% of global incidence and the number of cancer deaths accounts for 30%&#xD;
        of global deaths, both of which rank first in the world, with lung, liver, stomach, esophagus&#xD;
        and colorectal cancers having the highest mortality rates.&#xD;
  &#xD;
        At present, in addition to the traditional surgery, radiotherapy and chemotherapy treatments&#xD;
        for malignant tumours, with the advancement of biological sciences, tumour immunotherapy has&#xD;
        developed significantly, in which antibody drugs and cell therapy (chimeric antigen receptor&#xD;
        T cell, CAR-T) have products on the market. With the deepening research on the&#xD;
        characteristics of tumour cells and the differences in protein expression, therapeutic cancer&#xD;
        vaccines have gradually moved from theory to practice and have shown good performance in&#xD;
        clinical trials.&#xD;
  &#xD;
        The therapeutic cancer vaccine YB-01 is a therapeutic cancer vaccine formulation developed by&#xD;
        the Department of Nuclear Medicine of Peking Union Medical College Hospital and commissioned&#xD;
        to be produced by Zhaoyan Biologicals, a company with the qualification of Good manufacturing&#xD;
        practice (GMP), and developed by Yuanben (Zhuhai Hengqin) Biotech Co. YB-01 cancer vaccine is&#xD;
        a recombinant fusion protein with aluminium adjuvant and CpG182 adjuvant, and its core&#xD;
        component is Mucin N-terminal region (MNR), which is specifically expressed by cancer cells.&#xD;
        Mucin1 (MUC1) is a glycoprotein that plays a pivotal role in tumour formation, growth,&#xD;
        invasion, signalling, pro-angiogenesis, anoxia and chemoresistance. Normal epithelial cells&#xD;
        exist with low expression of MUC1, whereas cancerous cells have high expression of MUC1&#xD;
        (100-fold increase), and this differential expression is due to the fact that it is&#xD;
        abnormally pronounced in biliary pancreatic carcinoma, cholangiocarcinoma, gastric&#xD;
        adenocarcinoma, breast carcinoma and neuroendocrine pancreatic carcinoma, so that&#xD;
        vaccine-induced immune response is only directed against the cancerous cells, but not against&#xD;
        the normal tissues, and non-glycosylated MUC1 has become an important target for cancer&#xD;
        therapy.YB- 01 vaccine targets MUC1 and enhances humoral and cell-mediated immune responses&#xD;
        through immunity to MUC1 peptide or MUC1 peptide-activated dendritic cells (DC).DC cells&#xD;
        activate CD4 T cells, which promotes the activation of B cells to produce antibodies against&#xD;
        MUC1, and DC cells also activate CD8 T cells, which target and kill tumour cells that express&#xD;
        MUC1. cells expressing MUC1.&#xD;
  &#xD;
        Approximately 9-18 subjects will be recruited in this study. The investigational drug used in&#xD;
        the study is the therapeutic cancer vaccine YB-01, and the study is designed to investigate&#xD;
        the safety, tolerability, and preliminary efficacy of the vaccine in subjects with advanced&#xD;
        solid tumours.&#xD;
      </textblock>
    </detailed_description>
    <overall_status>Not yet recruiting</overall_status>
    <start_date type="Anticipated">August 2023</start_date>
    <completion_date type="Anticipated">December 2024</completion_date>
    <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
    <phase>Phase 2</phase>
    <study_type>Interventional</study_type>
    <has_expanded_access>No</has_expanded_access>
    <study_design_info>
      <allocation>N/A</allocation>
      <intervention_model>Single Group Assignment</intervention_model>
      <intervention_model_description>The study flow included a screening period (week -4 to day -1), a treatment period (day 1 to week 8 or 16, including a DLT observation period on days 1-28), an end-of-treatment visit, and a survival follow-up. The treatment period included the initial treatment period (day 1 to week 8) and the augmentation period (week 12 to week 16). Subjects after signing and providing formal informed consent entered the screening period, during which eight separate administrations of the vaccine were administered, of which the investigator determined whether to continue treatment from week 8 to week 12 based on a combination of efficacy, safety, and adherence.</intervention_model_description>
      <primary_purpose>Treatment</primary_purpose>
      <masking>None (Open Label)</masking>
    </study_design_info>
    <primary_outcome>
      <measure>The safety of the vaccine using CTCAE v5.0 based on the number of patients with treatment-related adverse events.</measure>
      <time_frame>8~12weeks</time_frame>
      <description>Assess the safety of the vaccine using CTCAE v5.0 based on the number of patients with treatment-related adverse events.</description>
    </primary_outcome>
    <primary_outcome>
      <measure>DLT</measure>
      <time_frame>8~12weeks</time_frame>
      <description>Inject 0.5 to 2.0 mg of vaccine intramuscularly over a 16-week cycle to determine dose-limiting toxicity (DLT).</description>
    </primary_outcome>
    <primary_outcome>
      <measure>RP2D</measure>
      <time_frame>8~12weeks</time_frame>
      <description>Determine if the maximum tolerated dose is among the doses explored and determine the recommended phase 2 dose (RP2D) of the vaccine.</description>
    </primary_outcome>
    <secondary_outcome>
      <measure>Preliminary assessment of the effectiveness of therapeutic oncology vaccines in advanced solid tumors.</measure>
      <time_frame>2years</time_frame>
      <description>Preliminary assessment of the effectiveness of therapeutic oncology vaccines in advanced solid tumors.</description>
    </secondary_outcome>
    <number_of_arms>1</number_of_arms>
    <enrollment type="Anticipated">20</enrollment>
    <condition>Solid Tumor, Adult</condition>
    <arm_group>
      <arm_group_label>MUC1 Vaccine</arm_group_label>
      <arm_group_type>Experimental</arm_group_type>
      <description>Enrollment by cohort from the starting dose of the trial and proceed to the next higher dose level if no one of the first 3 subjects develops DLT. If 1 of the 3 subjects develops DLT, then 3 additional subjects will be added to that dose level for a total of 6 subjects.&#xD;
  If only 1 of 6 subjects develops DLT, proceed to the next higher dose level. If no fewer than 2 of the 6 subjects develop DLT, no more subjects will be added to that dose level and dose escalation will cease. The Safety Monitoring Committee (SMC) decides whether to use the intermediate dose as the next dose level for the study. Until the maximum sample size specified in the protocol or the SMC decides to terminate the dose increment.each subject receives only one dose group of study drug (during the incremental period, subjects may receive a reduced dose to continue treatment after the investigator has assessed the risk-benefit for safety reasons; dose increments are not permitted for the same subject).</description>
    </arm_group>
    <intervention>
      <intervention_type>Drug</intervention_type>
      <intervention_name>Vaccine</intervention_name>
      <description>Dose-escalation trial, according to the classic &quot;3+3&quot; model, divided into three dose levels of 0.5 mg, 1.0 mg, 2.0 mg for enrollment, is expected to enroll a total of 9-18 subjects (0.5 mg dose group to be enrolled in 3-6 subjects, 1.0 mg dose group is proposed to be enrolled in 3-6 subjects, 2.0 mg dose group is proposed to be enrolled in 3-6 subjects, and the dose group is proposed to be enrolled in 3-6 subjects, and the dose group is proposed to be enrolled in 3-6 subjects. dose group is proposed to include 3-6 subjects).</description>
      <arm_group_label>MUC1 Vaccine</arm_group_label>
    </intervention>
    <eligibility>
      <criteria>
        <textblock>
          Inclusion Criteria:&#xD;
  &#xD;
            1. screening period patients are able to understand and voluntarily sign an informed&#xD;
               consent form;&#xD;
  &#xD;
            2. males and females between the ages of 18 and 75 years (both ends included);&#xD;
  &#xD;
            3. expected survival ≥ 3 months;&#xD;
  &#xD;
            4. advanced subjects with histologically or cytologically proven advanced solid tumors&#xD;
               who have failed standard multiline therapy;&#xD;
  &#xD;
            5. have at least one measurable lesion (i.e., mass ≥10 mm in diameter and malignant lymph&#xD;
               node ≥15 mm in short diameter on enhanced scan with layer thickness ≤5 mm on spiral&#xD;
               CT) according to the efficacy evaluation criteria for solid tumors, RECIST version 1.1&#xD;
               (see Appendix 4, Criteria for Evaluating the Efficacy of Solid Tumor Treatments);&#xD;
  &#xD;
            6. Fresh or archived tumor tissue samples within 5 years are available for central&#xD;
               laboratory testing during the screening period (if they are truly unavailable, this&#xD;
               will not affect enrollment);&#xD;
  &#xD;
            7. ECOG physical status score of 0 to 2;&#xD;
  &#xD;
            8. treatment with other anti-tumor drugs (e.g., chemotherapy, hormone therapy,&#xD;
               immunotherapy, antibody therapy, radiotherapy) prior to the first dose exceeds the 5&#xD;
               half-life of the drug or more than 4 weeks before the first dose (whichever is&#xD;
               shorter);&#xD;
  &#xD;
            9. Organ function levels must meet the following requirements (no blood or blood product&#xD;
               transfusion, hematopoietic stimulating factor, albumin, or blood product use within 14&#xD;
               days prior to the examination): absolute neutrophil count (ANC) ≥ 1.5 × 109/L,&#xD;
               platelet count (PLT) ≥ 75 × 109/L, hemoglobin (Hb) ≥ 90 g/L; serum total bilirubin&#xD;
               (TBIL) ≤ 1.5 Total bilirubin (TBIL) ≤1.5 times the upper limit of normal value,&#xD;
               glutamic transaminase (AST) and alanine aminotransferase (ALT) ≤2.5 times the upper&#xD;
               limit of normal value (if liver metastasis is present, total bilirubin ≤3 times the&#xD;
               upper limit of normal value, AST and ALT ≤5 times the upper limit of normal value are&#xD;
               allowed). 10;&#xD;
  &#xD;
           10. Pre-menopausal women of childbearing potential must undergo a pregnancy test within 7&#xD;
               days prior to the start of treatment, and the result of the pregnancy test must be&#xD;
               negative and non-lactating; women without childbearing potential may not undergo a&#xD;
               pregnancy test and contraception, provided they are over 50 years of age, have not&#xD;
               used hormone therapy and have stopped menstruating for at least 12 months, or have&#xD;
               been sterilized. All enrolled subjects (either male or female) should use adequate&#xD;
               barrier contraception throughout the treatment period and for 3 months after&#xD;
               completion of treatment.&#xD;
  &#xD;
           11. Other toxicity parameters must be NCI-CTCAE v.5.0 Grade 0 or 1.&#xD;
  &#xD;
          Exclusion Criteria:&#xD;
  &#xD;
            1. Subjects who require long-term systemic application of anti-allergic medications or&#xD;
               who have a history of life-threatening allergic reactions to any vaccine or&#xD;
               medication;&#xD;
  &#xD;
            2. those with symptomatic or rapidly progressing central system metastases. Presence of&#xD;
               extensive pulmonary metastases causing respiratory distress; subjects with tumours in&#xD;
               close proximity to or invading large blood vessels or nerves;&#xD;
  &#xD;
            3. new cerebrovascular accidents (including ischaemic stroke, haemorrhagic stroke and&#xD;
               transient ischaemic attack) within 6 months prior to screening;&#xD;
  &#xD;
            4. acute myocardial infarction, uncontrolled angina pectoris, uncontrolled arrhythmia,&#xD;
               severe heart failure (see Appendix 3, New York Heart Association's Heart Failure&#xD;
               Classification Criteria, NYHA Class ≥ III) and other cardiovascular diseases within 6&#xD;
               months prior to screening;&#xD;
  &#xD;
            5. have received immunomodulatory medications within 4 weeks prior to the date of first&#xD;
               vaccination (D1), including, but not limited to, IL-2, CTLA-4 inhibitors, CD40&#xD;
               agonists, CD137 agonists, and IFN-alpha (except for high-risk surgical subjects using&#xD;
               IFN-alpha as an adjuvant therapy if IFN-alpha therapy was discontinued within the 4&#xD;
               weeks prior to the date of the trial);&#xD;
  &#xD;
            6. those with a history of renal insufficiency with serum creatinine levels greater than&#xD;
               1.5 times the upper limit of normal;&#xD;
  &#xD;
            7. have received a blood transfusion, erythropoietin (EPO), granulocyte&#xD;
               colony-stimulating factor (G-CSF), or granulocyte-macrophage colony-stimulating factor&#xD;
               (GM-CSF) within 2 weeks prior to the first dose of drug;&#xD;
  &#xD;
            8. subjects with skin conditions that may prevent intradermal vaccine from reaching the&#xD;
               target area (e.g., psoriasis);&#xD;
  &#xD;
            9. subjects in the Screening Period who continue to have adverse reactions from prior&#xD;
               anti-neoplastic therapy that have not been restored to a CTCAE Version 5.0 grade&#xD;
               rating of ≤ Grade 1 (with the exception of alopecia and platinum-induced neurotoxicity&#xD;
               of ≤ Grade 2);&#xD;
  &#xD;
           10. need for concomitant use of steroidal hormonal medications (tumour or non-tumour&#xD;
               related disease); exceptions may be made for those requiring topical (not applied to&#xD;
               the vaccination site) or inhaled steroids;&#xD;
  &#xD;
           11. the presence of active or uncontrollable infections requiring systemic therapy (except&#xD;
               for simple urinary tract infections or upper respiratory tract infections) in the&#xD;
               subject within 4 weeks prior to screening; and the presence of antibodies to the Human&#xD;
               Immunodeficiency Virus (HIV), hepatitis B Surface Antigen (SAB) positive and/or&#xD;
               hepatitis B Core Antibody (HBCO) positive with Hepatitis B Virus (HBV)&#xD;
               Deoxyribonucleic Acid (DNA) &gt;1000 copies/mL and Hepatitis C virus (HCV) antibodies on&#xD;
               virological testing during the Screening Period, Subjects who are positive for&#xD;
               antibodies specific to syphilis spirochetes;&#xD;
  &#xD;
           12. poorly controlled hypertension (defined as systolic blood pressure ≥160 mmHg and/or&#xD;
               diastolic blood pressure ≥100 mmHg) after treatment;&#xD;
  &#xD;
           13. subjects with a history of autoimmune disease [e.g., the following, but not limited&#xD;
               to: interstitial pneumonitis, uveitis, enteritis, hepatitis, pituitary gland&#xD;
               inflammation, vasculitis, nephritis, hyperthyroidism, hypothyroidism (hypothyroidism&#xD;
               without clinical symptoms or hypothyroidism due to radiotherapy may be included),&#xD;
               subjects with vitiligo or cured asthma that does not currently require any&#xD;
               intervention may be included, subjects requiring bronchodilators for medical&#xD;
               intervention cannot be included];&#xD;
  &#xD;
           14. subjects with active ulcers or gastrointestinal bleeding during the Screening Period;&#xD;
  &#xD;
           15. subjects who have received a previous similar therapeutic cancer vaccine or who have&#xD;
               received another vaccine within 4 weeks prior to Screening;&#xD;
  &#xD;
           16. subjects with congenital or acquired immunodeficiency;&#xD;
  &#xD;
           17. subjects who have participated in other clinical trials within 1 month prior to&#xD;
               screening;&#xD;
  &#xD;
           18. subjects with known alcohol or drug addiction;&#xD;
  &#xD;
           19. subjects who, in the opinion of the investigator, have an underlying health condition,&#xD;
               mental condition, or social condition that makes the subject unable or unwilling to&#xD;
               comply with the study protocol&#xD;
  &#xD;
           20. any other condition which, in the opinion of the Investigator, makes participation in&#xD;
               this study inappropriate.&#xD;
        </textblock>
      </criteria>
      <gender>All</gender>
      <minimum_age>18 Years</minimum_age>
      <maximum_age>75 Years</maximum_age>
      <healthy_volunteers>No</healthy_volunteers>
    </eligibility>
    <overall_contact>
      <last_name>Fang Li, MD</last_name>
      <phone>+86-010-69154417</phone>
      <email>lifang@pumch.cn</email>
    </overall_contact>
    <location>
      <facility>
        <name>Peking Union Medical College Hospital</name>
        <address>
          <city>Beijing</city>
          <state>Beijing</state>
          <zip>100730</zip>
          <country>China</country>
        </address>
      </facility>
      <contact>
        <last_name>Fang Li, MD</last_name>
        <phone>+86-010-69154417</phone>
        <email>lifang@pumch.cn</email>
      </contact>
    </location>
    <location_countries>
      <country>China</country>
    </location_countries>
    <reference>
      <citation>Arnold M, Morgan E, Rumgay H, Mafra A, Singh D, Laversanne M, Vignat J, Gralow JR, Cardoso F, Siesling S, Soerjomataram I. Current and future burden of breast cancer: Global statistics for 2020 and 2040. Breast. 2022 Dec;66:15-23. doi: 10.1016/j.breast.2022.08.010. Epub 2022 Sep 2.</citation>
      <PMID>36084384</PMID>
    </reference>
    <reference>
      <citation>Rumgay H, Shield K, Charvat H, Ferrari P, Sornpaisarn B, Obot I, Islami F, Lemmens VEPP, Rehm J, Soerjomataram I. Global burden of cancer in 2020 attributable to alcohol consumption: a population-based study. Lancet Oncol. 2021 Aug;22(8):1071-1080. doi: 10.1016/S1470-2045(21)00279-5.</citation>
      <PMID>34270924</PMID>
    </reference>
    <reference>
      <citation>O'Donnell JS, Teng MWL, Smyth MJ. Cancer immunoediting and resistance to T cell-based immunotherapy. Nat Rev Clin Oncol. 2019 Mar;16(3):151-167. doi: 10.1038/s41571-018-0142-8.</citation>
      <PMID>30523282</PMID>
    </reference>
    <reference>
      <citation>Lei K, Kurum A, Kaynak M, Bonati L, Han Y, Cencen V, Gao M, Xie YQ, Guo Y, Hannebelle MTM, Wu Y, Zhou G, Guo M, Fantner GE, Sakar MS, Tang L. Cancer-cell stiffening via cholesterol depletion enhances adoptive T-cell immunotherapy. Nat Biomed Eng. 2021 Dec;5(12):1411-1425. doi: 10.1038/s41551-021-00826-6. Epub 2021 Dec 6.</citation>
      <PMID>34873307</PMID>
    </reference>
    <reference>
      <citation>Riley RS, June CH, Langer R, Mitchell MJ. Delivery technologies for cancer immunotherapy. Nat Rev Drug Discov. 2019 Mar;18(3):175-196. doi: 10.1038/s41573-018-0006-z.</citation>
      <PMID>30622344</PMID>
    </reference>
    <reference>
      <citation>Szeto GL, Finley SD. Integrative Approaches to Cancer Immunotherapy. Trends Cancer. 2019 Jul;5(7):400-410. doi: 10.1016/j.trecan.2019.05.010.</citation>
      <PMID>31311655</PMID>
    </reference>
    <reference>
      <citation>Zhang Y, Zhang Z. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol. 2020 Aug;17(8):807-821. doi: 10.1038/s41423-020-0488-6. Epub 2020 Jul 1.</citation>
      <PMID>32612154</PMID>
    </reference>
    <reference>
      <citation>Gao T, Cen Q, Lei H. A review on development of MUC1-based cancer vaccine. Biomed Pharmacother. 2020 Dec;132:110888. doi: 10.1016/j.biopha.2020.110888. Epub 2020 Oct 21.</citation>
      <PMID>33113416</PMID>
    </reference>
    <reference>
      <citation>Nabavinia MS, Gholoobi A, Charbgoo F, Nabavinia M, Ramezani M, Abnous K. Anti-MUC1 aptamer: A potential opportunity for cancer treatment. Med Res Rev. 2017 Nov;37(6):1518-1539. doi: 10.1002/med.21462. Epub 2017 Jul 31.</citation>
      <PMID>28759115</PMID>
    </reference>
    <reference>
      <citation>Hossain MK, Wall KA. Immunological Evaluation of Recent MUC1 Glycopeptide Cancer Vaccines. Vaccines (Basel). 2016 Jul 26;4(3):25. doi: 10.3390/vaccines4030025.</citation>
      <PMID>27472370</PMID>
    </reference>
    <reference>
      <citation>Park JA, Park S, Park HB, Han MK, Lee Y. MUC1-C Contributes to the Maintenance of Human Embryonic Stem Cells and Promotes Somatic Cell Reprogramming. Stem Cells Dev. 2021 Nov 1;30(21):1082-1091. doi: 10.1089/scd.2021.0185. Epub 2021 Oct 18.</citation>
      <PMID>34514853</PMID>
    </reference>
    <reference>
      <citation>Rajabi H, Kufe D. MUC1-C Oncoprotein Integrates a Program of EMT, Epigenetic Reprogramming and Immune Evasion in Human Carcinomas. Biochim Biophys Acta Rev Cancer. 2017 Aug;1868(1):117-122. doi: 10.1016/j.bbcan.2017.03.003. Epub 2017 Mar 14.</citation>
      <PMID>28302417</PMID>
    </reference>
    <reference>
      <citation>Nath S, Mukherjee P. MUC1: a multifaceted oncoprotein with a key role in cancer progression. Trends Mol Med. 2014 Jun;20(6):332-42. doi: 10.1016/j.molmed.2014.02.007. Epub 2014 Mar 22.</citation>
      <PMID>24667139</PMID>
    </reference>
    <reference>
      <citation>Chen W, Zhang Z, Zhang S, Zhu P, Ko JK, Yung KK. MUC1: Structure, Function, and Clinic Application in Epithelial Cancers. Int J Mol Sci. 2021 Jun 18;22(12):6567. doi: 10.3390/ijms22126567.</citation>
      <PMID>34207342</PMID>
    </reference>
    <reference>
      <citation>Macao B, Johansson DG, Hansson GC, Hard T. Autoproteolysis coupled to protein folding in the SEA domain of the membrane-bound MUC1 mucin. Nat Struct Mol Biol. 2006 Jan;13(1):71-6. doi: 10.1038/nsmb1035. Epub 2005 Dec 20.</citation>
      <PMID>16369486</PMID>
    </reference>
    <reference>
      <citation>Raina D, Kharbanda S, Kufe D. The MUC1 oncoprotein activates the anti-apoptotic phosphoinositide 3-kinase/Akt and Bcl-xL pathways in rat 3Y1 fibroblasts. J Biol Chem. 2004 May 14;279(20):20607-12. doi: 10.1074/jbc.M310538200. Epub 2004 Mar 3.</citation>
      <PMID>14999001</PMID>
    </reference>
    <reference>
      <citation>Ota S, Miyashita M, Yamagishi Y, Ogasawara M. Baseline immunity predicts prognosis of pancreatic cancer patients treated with WT1 and/or MUC1 peptide-loaded dendritic cell vaccination and a standard chemotherapy. Hum Vaccin Immunother. 2021 Dec 2;17(12):5563-5572. doi: 10.1080/21645515.2021.2003645. Epub 2021 Dec 17.</citation>
      <PMID>34919493</PMID>
    </reference>
    <verification_date>August 2023</verification_date>
    <study_first_submitted>May 4, 2023</study_first_submitted>
    <study_first_submitted_qc>August 3, 2023</study_first_submitted_qc>
    <study_first_posted type="Actual">August 14, 2023</study_first_posted>
    <last_update_submitted>August 3, 2023</last_update_submitted>
    <last_update_submitted_qc>August 3, 2023</last_update_submitted_qc>
    <last_update_posted type="Actual">August 14, 2023</last_update_posted>
    <responsible_party>
      <responsible_party_type>Sponsor</responsible_party_type>
    </responsible_party>
    <keyword>vaccine</keyword>
    <keyword>Mucin 1</keyword>
    <keyword>MUC1</keyword>
    <keyword>malignant tumor</keyword>
    <condition_browse>
      <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
      <mesh_term>Neoplasms</mesh_term>
    </condition_browse>
    <patient_data>
      <sharing_ipd>No</sharing_ipd>
    </patient_data>
    <!-- Results have not yet been posted for this study                                          -->
  </clinical_study>
  
  
text: download date: ClinicalTrials.gov processed this data on September 20, 2023
  link text: Link to the current ClinicalTrials.gov record.
  url: https://clinicaltrials.gov/ct2/show/NCT05986981
  org study id: PekingUMCHVaccineMUC1
  nct id: NCT05986981
  lead sponsor: 
  is fda regulated drug: No
  is fda regulated device: No
  This is an investigator-initiated, single-center, open, single-arm, exploratory study of a
        therapeutic cancer vaccine for the treatment of advanced solid tumors. A dose-escalation
        trial is being conducted in subjects diagnosed with advanced solid tumors to evaluate the
        safety and tolerability of the cancer vaccine in subjects with advanced solid tumors and to
        preliminarily evaluate the efficacy of the tumor vaccine in subjects with advanced solid
        tumors.
  Malignant tumours have become one of the major public health problems that seriously threaten
        human health. According to the latest global cancer burden data for 2020 released by the
        International Agency for Research on Cancer (IARC) of the World Health Organization (WHO),
        there will be 19.29 million new cancer cases and 9.96 million deaths globally in 2020; in
        2020, there will be 4.57 million new cancer cases and 3 million deaths in China, with the
        number of new cancers in China accounting for 23.7% of the global incidence and 30% of the
        global deaths, both of which are the highest in the world. The number of new cancer cases in
        China accounts for 23.7% of global incidence and the number of cancer deaths accounts for 30%
        of global deaths, both of which rank first in the world, with lung, liver, stomach, esophagus
        and colorectal cancers having the highest mortality rates.
  
        At present, in addition to the traditional surgery, radiotherapy and chemotherapy treatments
        for malignant tumours, with the advancement of biological sciences, tumour immunotherapy has
        developed significantly, in which antibody drugs and cell therapy (chimeric antigen receptor
        T cell, CAR-T) have products on the market. With the deepening research on the
        characteristics of tumour cells and the differences in protein expression, therapeutic cancer
        vaccines have gradually moved from theory to practice and have shown good performance in
        clinical trials.
  
        The therapeutic cancer vaccine YB-01 is a therapeutic cancer vaccine formulation developed by
        the Department of Nuclear Medicine of Peking Union Medical College Hospital and commissioned
        to be produced by Zhaoyan Biologicals, a company with the qualification of Good manufacturing
        practice (GMP), and developed by Yuanben (Zhuhai Hengqin) Biotech Co. YB-01 cancer vaccine is
        a recombinant fusion protein with aluminium adjuvant and CpG182 adjuvant, and its core
        component is Mucin N-terminal region (MNR), which is specifically expressed by cancer cells.
        Mucin1 (MUC1) is a glycoprotein that plays a pivotal role in tumour formation, growth,
        invasion, signalling, pro-angiogenesis, anoxia and chemoresistance. Normal epithelial cells
        exist with low expression of MUC1, whereas cancerous cells have high expression of MUC1
        (100-fold increase), and this differential expression is due to the fact that it is
        abnormally pronounced in biliary pancreatic carcinoma, cholangiocarcinoma, gastric
        adenocarcinoma, breast carcinoma and neuroendocrine pancreatic carcinoma, so that
        vaccine-induced immune response is only directed against the cancerous cells, but not against
        the normal tissues, and non-glycosylated MUC1 has become an important target for cancer
        therapy.YB- 01 vaccine targets MUC1 and enhances humoral and cell-mediated immune responses
        through immunity to MUC1 peptide or MUC1 peptide-activated dendritic cells (DC).DC cells
        activate CD4 T cells, which promotes the activation of B cells to produce antibodies against
        MUC1, and DC cells also activate CD8 T cells, which target and kill tumour cells that express
        MUC1. cells expressing MUC1.
  
        Approximately 9-18 subjects will be recruited in this study. The investigational drug used in
        the study is the therapeutic cancer vaccine YB-01, and the study is designed to investigate
        the safety, tolerability, and preliminary efficacy of the vaccine in subjects with advanced
        solid tumours.
  allocation: N/A
  intervention model: Single Group Assignment
  intervention model description: The study flow included a screening period (week -4 to day -1), a treatment period (day 1 to week 8 or 16, including a DLT observation period on days 1-28), an end-of-treatment visit, and a survival follow-up. The treatment period included the initial treatment period (day 1 to week 8) and the augmentation period (week 12 to week 16). Subjects after signing and providing formal informed consent entered the screening period, during which eight separate administrations of the vaccine were administered, of which the investigator determined whether to continue treatment from week 8 to week 12 based on a combination of efficacy, safety, and adherence.
  primary purpose: Treatment
  masking: None (Open Label)
  measure: The safety of the vaccine using CTCAE v5.0 based on the number of patients with treatment-related adverse events.
  time frame: 8~12weeks
  description: Assess the safety of the vaccine using CTCAE v5.0 based on the number of patients with treatment-related adverse events.
  measure: DLT
  time frame: 8~12weeks
  description: Inject 0.5 to 2.0 mg of vaccine intramuscularly over a 16-week cycle to determine dose-limiting toxicity (DLT).
  measure: RP2D
  time frame: 8~12weeks
  description: Determine if the maximum tolerated dose is among the doses explored and determine the recommended phase 2 dose (RP2D) of the vaccine.
  measure: Preliminary assessment of the effectiveness of therapeutic oncology vaccines in advanced solid tumors.
  time frame: 2years
  description: Preliminary assessment of the effectiveness of therapeutic oncology vaccines in advanced solid tumors.
  arm group label: MUC1 Vaccine
  arm group type: Experimental
  description: Enrollment by cohort from the starting dose of the trial and proceed to the next higher dose level if no one of the first 3 subjects develops DLT. If 1 of the 3 subjects develops DLT, then 3 additional subjects will be added to that dose level for a total of 6 subjects.
  If only 1 of 6 subjects develops DLT, proceed to the next higher dose level. If no fewer than 2 of the 6 subjects develop DLT, no more subjects will be added to that dose level and dose escalation will cease. The Safety Monitoring Committee (SMC) decides whether to use the intermediate dose as the next dose level for the study. Until the maximum sample size specified in the protocol or the SMC decides to terminate the dose increment.each subject receives only one dose group of study drug (during the incremental period, subjects may receive a reduced dose to continue treatment after the investigator has assessed the risk-benefit for safety reasons; dose increments are not permitted for the same subject).
  intervention type: Drug
  intervention name: Vaccine
  description: Dose-escalation trial, according to the classic "3+3" model, divided into three dose levels of 0.5 mg, 1.0 mg, 2.0 mg for enrollment, is expected to enroll a total of 9-18 subjects (0.5 mg dose group to be enrolled in 3-6 subjects, 1.0 mg dose group is proposed to be enrolled in 3-6 subjects, 2.0 mg dose group is proposed to be enrolled in 3-6 subjects, and the dose group is proposed to be enrolled in 3-6 subjects, and the dose group is proposed to be enrolled in 3-6 subjects. dose group is proposed to include 3-6 subjects).
  arm group label: MUC1 Vaccine
  criteria: 
  gender: All
  minimum age: 18 Years
  maximum age: 75 Years
  healthy volunteers: No
  last name: Fang Li, MD
  phone: +86-010-69154417
  email: lifang@pumch.cn
  facility: 
  contact: 
  country: China
  citation: Arnold M, Morgan E, Rumgay H, Mafra A, Singh D, Laversanne M, Vignat J, Gralow JR, Cardoso F, Siesling S, Soerjomataram I. Current and future burden of breast cancer: Global statistics for 2020 and 2040. Breast. 2022 Dec;66:15-23. doi: 10.1016/j.breast.2022.08.010. Epub 2022 Sep 2.
  PMID: 36084384
  citation: Rumgay H, Shield K, Charvat H, Ferrari P, Sornpaisarn B, Obot I, Islami F, Lemmens VEPP, Rehm J, Soerjomataram I. Global burden of cancer in 2020 attributable to alcohol consumption: a population-based study. Lancet Oncol. 2021 Aug;22(8):1071-1080. doi: 10.1016/S1470-2045(21)00279-5.
  PMID: 34270924
  citation: O'Donnell JS, Teng MWL, Smyth MJ. Cancer immunoediting and resistance to T cell-based immunotherapy. Nat Rev Clin Oncol. 2019 Mar;16(3):151-167. doi: 10.1038/s41571-018-0142-8.
  PMID: 30523282
  citation: Lei K, Kurum A, Kaynak M, Bonati L, Han Y, Cencen V, Gao M, Xie YQ, Guo Y, Hannebelle MTM, Wu Y, Zhou G, Guo M, Fantner GE, Sakar MS, Tang L. Cancer-cell stiffening via cholesterol depletion enhances adoptive T-cell immunotherapy. Nat Biomed Eng. 2021 Dec;5(12):1411-1425. doi: 10.1038/s41551-021-00826-6. Epub 2021 Dec 6.
  PMID: 34873307
  citation: Riley RS, June CH, Langer R, Mitchell MJ. Delivery technologies for cancer immunotherapy. Nat Rev Drug Discov. 2019 Mar;18(3):175-196. doi: 10.1038/s41573-018-0006-z.
  PMID: 30622344
  citation: Szeto GL, Finley SD. Integrative Approaches to Cancer Immunotherapy. Trends Cancer. 2019 Jul;5(7):400-410. doi: 10.1016/j.trecan.2019.05.010.
  PMID: 31311655
  citation: Zhang Y, Zhang Z. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol. 2020 Aug;17(8):807-821. doi: 10.1038/s41423-020-0488-6. Epub 2020 Jul 1.
  PMID: 32612154
  citation: Gao T, Cen Q, Lei H. A review on development of MUC1-based cancer vaccine. Biomed Pharmacother. 2020 Dec;132:110888. doi: 10.1016/j.biopha.2020.110888. Epub 2020 Oct 21.
  PMID: 33113416
  citation: Nabavinia MS, Gholoobi A, Charbgoo F, Nabavinia M, Ramezani M, Abnous K. Anti-MUC1 aptamer: A potential opportunity for cancer treatment. Med Res Rev. 2017 Nov;37(6):1518-1539. doi: 10.1002/med.21462. Epub 2017 Jul 31.
  PMID: 28759115
  citation: Hossain MK, Wall KA. Immunological Evaluation of Recent MUC1 Glycopeptide Cancer Vaccines. Vaccines (Basel). 2016 Jul 26;4(3):25. doi: 10.3390/vaccines4030025.
  PMID: 27472370
  citation: Park JA, Park S, Park HB, Han MK, Lee Y. MUC1-C Contributes to the Maintenance of Human Embryonic Stem Cells and Promotes Somatic Cell Reprogramming. Stem Cells Dev. 2021 Nov 1;30(21):1082-1091. doi: 10.1089/scd.2021.0185. Epub 2021 Oct 18.
  PMID: 34514853
  citation: Rajabi H, Kufe D. MUC1-C Oncoprotein Integrates a Program of EMT, Epigenetic Reprogramming and Immune Evasion in Human Carcinomas. Biochim Biophys Acta Rev Cancer. 2017 Aug;1868(1):117-122. doi: 10.1016/j.bbcan.2017.03.003. Epub 2017 Mar 14.
  PMID: 28302417
  citation: Nath S, Mukherjee P. MUC1: a multifaceted oncoprotein with a key role in cancer progression. Trends Mol Med. 2014 Jun;20(6):332-42. doi: 10.1016/j.molmed.2014.02.007. Epub 2014 Mar 22.
  PMID: 24667139
  citation: Chen W, Zhang Z, Zhang S, Zhu P, Ko JK, Yung KK. MUC1: Structure, Function, and Clinic Application in Epithelial Cancers. Int J Mol Sci. 2021 Jun 18;22(12):6567. doi: 10.3390/ijms22126567.
  PMID: 34207342
  citation: Macao B, Johansson DG, Hansson GC, Hard T. Autoproteolysis coupled to protein folding in the SEA domain of the membrane-bound MUC1 mucin. Nat Struct Mol Biol. 2006 Jan;13(1):71-6. doi: 10.1038/nsmb1035. Epub 2005 Dec 20.
  PMID: 16369486
  citation: Raina D, Kharbanda S, Kufe D. The MUC1 oncoprotein activates the anti-apoptotic phosphoinositide 3-kinase/Akt and Bcl-xL pathways in rat 3Y1 fibroblasts. J Biol Chem. 2004 May 14;279(20):20607-12. doi: 10.1074/jbc.M310538200. Epub 2004 Mar 3.
  PMID: 14999001
  citation: Ota S, Miyashita M, Yamagishi Y, Ogasawara M. Baseline immunity predicts prognosis of pancreatic cancer patients treated with WT1 and/or MUC1 peptide-loaded dendritic cell vaccination and a standard chemotherapy. Hum Vaccin Immunother. 2021 Dec 2;17(12):5563-5572. doi: 10.1080/21645515.2021.2003645. Epub 2021 Dec 17.
  PMID: 34919493
  responsible party type: Sponsor
  mesh term: Neoplasms
  sharing ipd: No